From Harvard Massachusetts to Central South Hospital: Professor Chen Hongxiang's Global Perspective on Dermatology and Chinese Practice-宁点视界-清桥国际安保集团

From Harvard Massachusetts to Central South Hospital: Professor Chen Hongxiang's Global Perspective on Dermatology and Chinese Practice

Release time：2026-06-01 Source: Qingqiao Number of views：

Skin diseases have become one of the most common health problems worldwide. According to data from the Global Burden of Disease Study, there are approximatelynineteenBillion tothirtyMillions of people are troubled by at least one skin disease, accounting for nearly a quarter of the world's population, with new cases occurring every yearforty-six point nineBillion toforty-eight point sixBillion cases-Skin diseases have therefore become one of the main causes of non fatal disease burden worldwide, ranking among the top ten disabling diseases.two thousand and twenty-fiveYear, theseventy-eightFor the first time, the World Health Assembly has listed skin diseases as a global public health priority. This high-level commitment has pointed out the direction for global collaborative response - enhancing primary healthcare capabilities, utilizing digital technology, strengthening data monitoring, reducing key drug prices, and promoting inclusive research, which has become an international consensus.

In China, about 350 million people suffer from skin problems, and the outpatient volume of skin diseases ranks among the top three in general hospitals all year round. The development process of dermatology research in China can be summarized as "although the starting point is low, we are catching up quickly". Chinese dermatology, which officially developed after the founding of the People's Republic of China, has gone from being a blank slate to now being able to dominate top journals such as Nature and the New England Journal of Medicine, and leading the world in the development of certain new drugs. The strong national support, the struggle of several generations of scholars, the comprehensive talent cultivation, and the huge clinical demand have jointly driven this profound leapfrog progress. Nowadays, research on skin diseases in China is entering a new stage of high-quality development and playing a more active role in global skin health governance.

Chen Hongxiang, director of the Department of Dermatology at Zhongnan Hospital of Wuhan University, is an outstanding representative of this era. He has worked as a postdoctoral researcher at the Skin Biology Research Center of Massachusetts General Hospital at Harvard Medical School in the United States, and has pursued further studies at top international institutions such as Kyushu University in Japan. He has extensive management and clinical experience at Huazhong University of Science and Technology Union Hospital Shenzhen and Wuhan Union Hospital. He successfully treated centenarian pemphigus patients and severe drug rash cases, demonstrating top-notch clinical skills. Academically, he has led 7 National Natural Science Foundation projects, published over 80 SCI papers, served as an editorial board member for multiple authoritative journals, and translated several classic works. He attaches great importance to international exchanges and actively promotes in-depth dialogue on the diagnosis and treatment concepts of skin diseases between China and foreign countries. In the construction of the department, we will vigorously build a dermatology specialty medical alliance, establish a hair medicine center and an internationally certified urticaria specialty clinic. Chen Hongxiang actively participates in public welfare science popularization and grassroots free clinics. He has planned and produced CCTV's "Light of Technology" science popularization film and multiple provincial and municipal mainstream media science popularization programs. He is an outstanding representative of young and middle-aged dermatologists who have returned from studying abroad and rooted in Wuhan.

In this episode of "Ningdian Interview", Director Chen Hongxiang is invited to share his cutting-edge observations and profound thoughts on core topics such as current trends in dermatology research and development, integrated Chinese and Western medicine practices, prospects for artificial intelligence applications, and discipline construction, based on his rich international exchange experience and frontline clinical experience.

WHO has listed skin diseases as a global public health priority, and 350 million people in China are also affected by skin problems. What are the main factors affecting the occurrence of skin diseases? What are the most concerned trends and challenges in the field of global skin disease prevention and treatment?

Chen Hongxiang: Dermatology may seem like a "small department", but it actually deals with the skin, which is the largest organ in the human body and contains the most diseases. It consistently ranks among the top three in outpatient volume in most general hospitals, with a very high incidence rate and public demand for medical treatment. The skin is in direct contact with the external environment and is the largest barrier for the human body. Skin problems are not only manifested as redness, itching, or rash, but are often associated with immune dysfunction, infection, genetics, environmental exposure, as well as psychological, metabolic, and other factors. Therefore, skin diseases are no longer just personal health issues, but have become important topics in the fields of public health and social psychology.

The main factors affecting the onset of skin diseases include the following aspects. Firstly, environmental stimuli. Skin exposure to external factors such as heat, ultraviolet radiation, humid and hot environments, chemical irritants, and allergens can all induce or exacerbate skin diseases. A former American military doctor who participated in a fungal course during the Vietnam War mentioned that fungal infections (such as athlete's foot) are prone to occur in humid and hot jungle environments, causing soldiers to lose their mobility and seriously affecting the combat effectiveness of the troops. Secondly, immune and inflammatory factors. Many stubborn skin diseases, such as psoriasis (commonly known as "psoriasis"), atopic dermatitis, lupus erythematosus, are essentially manifestations of immune diseases in the skin, with a high incidence rate and great trouble for patients. Thirdly, infectious factors. COVID-19, fungi, bacteria, viruses and insect borne infectious diseases can all be displayed through the first barrier of the skin, and the early symptoms of monkeypox and other diseases often appear on the skin. Fourth, the impact of lifestyle. Modern lifestyles such as staying up late, stress, obesity, and lack of exercise can alter the immune and inflammatory state of the skin, leading to worsening psoriasis, adolescent acne (pimples), hair loss, and chronic allergies (such as urticaria and eczema) becoming increasingly prominent.

There are three main trends and challenges that are currently receiving the most attention in the field of global skin disease prevention and treatment. One is the rise of precision therapy and biologics. Multiple monoclonal antibody drugs have been developed for stubborn skin diseases such as vitiligo, psoriasis, and eczema. Choosing the right drugs can effectively control previously difficult to control diseases, marking the entry of precision medicine into the era of skin disease treatment. The second is the promotion of the concept of whole course management. Skin diseases are no longer the management of a single disease, for example, psoriasis often coexists with arthritis, heart disease, intestinal disease, metabolic syndrome, etc. as the medical history prolongs, requiring comprehensive and continuous care. The third is grassroots capacity building and medical equity. Many skin diseases do not necessarily require centralized diagnosis and treatment in large hospitals. By providing standardized training to grassroots doctors and community organizations, patients can achieve early identification and standardized diagnosis and treatment nearby. How to enhance grassroots diagnosis and treatment capabilities and narrow the gap in medical resources is an important challenge facing the world.

In the above context, how do you evaluate the current position of Chinese dermatology research in the international academic coordinate system? What is the development positioning of skin disease prevention and treatment in China?

在以上背景下，您如何评价当前中国皮肤病研究在国际学术坐标系中的位置？中国皮肤病防治的发展定位如何？

Chen Hongxiang: The modern development of dermatology in China began after the founding of the People's Republic of China, but it developed very early in Europe and America. For example, the H ô pital Saint Louis Hospital, established in 1607, was the first dermatology center to establish a systematic teaching, classification, and research system. It is recognized as the cradle of modern dermatology, and many skin diseases and signs are named after the doctors at the hospital. In the early days, China largely learned, introduced, and followed Western medicine.

However, after decades of effort, the progress of dermatology in China has been significant and has formed several prominent characteristics. Firstly, there is abundant resources: China has a large population base, a wide spectrum of diseases, and a large number of patients, which provides a unique population foundation for conducting clinical research, real-world research, and disease queue construction. Secondly, Chinese dermatologists have extremely rich clinical experience. For example, in terms of outpatient volume, a dermatologist can receive up to 60 to 100 patients per day. However, under the appointment system in Western countries, it is not easy to handle one patient every half an hour to one hour. Long term high-intensity frontline diagnosis and treatment practice has enabled Chinese doctors to accumulate strong practical abilities in common diseases, frequently occurring diseases, difficult diseases, and severe skin diseases. At the same time, the combination of traditional Chinese and Western medicine has a lower cost and is suitable for promotion and application at the grassroots level. In addition, in terms of scientific research, the progress of dermatology in China is also rapid. There have been many original achievements in the fields of immune skin diseases, skin tumors, skin beauty, and skin imaging, gradually entering the international platform and enabling good academic dialogue with global peers.

However, we also need to be aware of the gap. Firstly, there is a lack of research on high-quality original mechanisms; Secondly, there are still shortcomings in the establishment of international multicenter clinical research and long-term follow-up cohorts; Thirdly, the discourse power in the formulation of international guidelines and consensus is weak, and the number of Chinese doctors who can participate is limited, and they rarely take on leading roles; Fourthly, there is still a need to vigorously strengthen the research and development of drugs and medical devices at their source.

Based on this international coordinate, the development positioning of skin disease prevention and treatment in China is: firstly, it should be based on the disease characteristics and prevention and treatment needs of the domestic population, and effectively solve the problems of Chinese patients themselves; At the same time, we should actively learn from the international forefront and deeply participate in global innovation cooperation; In addition, efforts should be made to promote health equity for grassroots patients and narrow the diagnosis and treatment gap between urban, rural, and regional areas. This is not only the responsibility of Chinese dermatologists, but also the core mission for future development.

What are the mainstream directions for treating skin diseases globally and in China at present? Based on your clinical and research experience, what practical problems do these therapies commonly face in promotion? How to truly benefit more patients?

Chen Hongxiang: Globally, dermatological treatment mainly includes the diagnosis and treatment of common skin diseases, prevention and treatment of sexually transmitted diseases, and medical beauty. In the treatment of skin diseases, targeted therapy and precision drug therapy have become core trends, especially monoclonal antibodies, small molecule targeted drugs, etc., which are increasingly widely used in "immune-mediated inflammatory skin diseases" such as psoriasis, atopic dermatitis, urticaria, vitiligo, acne, etc. At the same time, the treatment concept has shifted from simply "looking at the rash" to "looking at the whole person", emphasizing comprehensive management of the patient's cardiovascular, metabolic, joint, and psychological states, as skin problems are closely related to overall health and psychological well-being.

In China, in addition to keeping up with the pace of international targeted and precision treatment, integrated traditional Chinese and Western medicine treatment is a major feature. It should be pointed out that although the country has introduced multiple policies to support the development of traditional Chinese medicine, the role of traditional Chinese medicine in the field of dermatology still needs to be further strengthened. The combination of traditional Chinese and Western medicine is not applicable to all skin diseases: for infectious skin diseases, antibiotics, antiviral and antifungal drugs have clear effects, but the advantages of the combination of traditional Chinese and Western medicine are not obvious; However, in immune related diseases such as psoriasis, eczema, hair loss, etc., the combination of traditional Chinese and Western medicine has demonstrated unique therapeutic effects and advantages by regulating immune balance, using external treatment methods such as traditional Chinese medicine detergents, fire needles, plum blossom needles, cupping, fumigation and soaking.

In current healthcare, the main challenges are the high cost of targeted drugs and biologics, as well as the pressure to pay for individual diseases. To benefit more patients, we should actively leverage the advantages of combining traditional Chinese and Western medicine in terms of pharmacoeconomics and treatment accessibility. By optimizing treatment plans, we can reduce the cost of individual diseases, alleviate the burden on medical insurance and patients, promote the rational application of precision treatment and integrated traditional Chinese and Western medicine therapy, and enable patients with different types of diseases to receive appropriate and affordable treatment, thereby achieving broader health benefits.

You have repeatedly mentioned the application prospects of new technologies such as artificial intelligence in the field of skin diseases. What is the actual implementation effect of AI assisted diagnosis and other technologies in clinical practice at present? What are the key bottlenecks that need to be overcome?

Chen Hongxiang: The application prospects of artificial intelligence in the field of skin diseases are indeed worthy of high attention. At present, the implementation of AI technology in dermatology is still in its early stages, but dermatology can be said to be one of the most promising medical specialties for artificial intelligence, as the diagnosis of skin diseases highly relies on vision, including the color, shape, distribution, etc. of skin lesions. Therefore, image recognition has become the first application direction of AI in medicine. The first related medical paper published by the Stanford University team focuses on skin diseases and skin tumors, using mobile phone photos and skin mirror images for recognition.

In addition to image recognition, technologies such as medical big models, natural language processing, and the Internet of Things can also be used for clinical dermatology, disease management, and medical process optimization. China has begun to attach importance to and invest in this field, for example, Academician Zhang Pingwen, President of Wuhan University, led the establishment of the School of Artificial Intelligence and signed a contract with Central South Hospital of Wuhan University to establish the "Medical Artificial Intelligence Research Institute", promoting the connection between various clinical departments and AI teams, and finding practical application scenarios. In dermatology, AI can be used to assist in the screening of skin tumors, evaluate common diseases such as psoriasis, vitiligo, and hair loss (some skin mirror products with AI analysis functions have been implemented), record changes in skin lesions in chronic disease management, assess severity, remind follow-up medication, and assist grassroots doctors in basic diagnosis. Currently, many universities and companies in China are developing related software and applications.

However, there are still several key bottlenecks that need to be overcome. Firstly, AI training requires a large amount of high-quality annotated image datasets, but currently such datasets are still relatively lacking. Secondly, the good performance of AI models in a certain hospital does not necessarily mean that they can be equally effective in different regions or primary healthcare institutions, which involves the issue of model generalization ability. Thirdly, the definition of clinical responsibility boundaries is not yet clear. AI can serve as an assistant to assist doctors in producing reports and improving efficiency, but the final diagnosis must be reviewed and legally responsible by doctors, rather than AI itself. Overall, the implementation of AI in dermatology requires a mature process, and we are full of expectations for it, but we also need to approach its current development stage rationally.

You have worked at the Massachusetts General Hospital/Skin Biology Research Center at Harvard Medical School in the United States, and have led multiple national level research projects. You have also led teams to remote mountainous areas for free clinics and promoted the establishment of a dermatology specialty alliance covering counties and cities. Based on your extensive research and clinical experience, what is the typical conversion period from research to clinical practice? What are the main challenges faced in this conversion process? Where is the possible breakthrough point? Can the development of AI technology help shorten the conversion cycle?

Chen Hongxiang: Conversion itself is indeed very important. In recent years, the government and major universities have introduced relevant policies to promote the transformation of skin disease research from scientific research to clinical practice, but truly original results are still difficult to achieve. A basic research has found that it usually takes years or even decades for a diagnostic method, therapeutic drug, or management model to truly become clinically available. Especially in the development of new drugs, from target discovery, mechanism validation, animal experiments, drug optimization, safety evaluation, clinical trials to market application, the cycle is long and the risks are high. In the process of scientific research transformation, medical institutions mainly play the role of proposing clinical needs and undertaking clinical trials, which is an important battlefield for clinical research. As for the conversion cycle, ideally, it often takes a long time from mechanism research to final application, but the specific duration is difficult to generalize.

The main challenges of transformation are: high investment and high risk in original research; It is difficult for medical institutions to independently complete the full chain transformation from laboratory to market; At the same time, the development of new drugs and devices requires interdisciplinary collaboration and involves institutional issues such as intellectual property rights.

There are several possible breakthrough directions. Firstly, starting from clinical issues, targeting unmet needs of patients such as chronic itching, chronic recurrent fungal infections, severe drug rashes, etc., discovering problems and then seeking mechanisms in the laboratory, this reverse transformation pathway has unique advantages. Secondly, innovation in medical models is equally important and does not necessarily rely on new drugs or equipment. Forms such as remote consultations, AI assisted diagnosis, and specialized clinics can also benefit patients. Thirdly, the intersection of medicine and engineering is currently a very active direction of transformation. The intersection between dermatology and disciplines such as materials science, chemistry, and optical imaging is increasing. For example, our research partner Professor Tao Guangming's research group has developed a wearable fiber fabric with cooling function, which can integrate sensors to obtain physiological indicators. Such achievements have been published in high-level journals and have attracted cooperation in both civilian and military fields. Fourthly, the development of organoid technology provides a new approach for drug efficacy verification, which can partially replace animal experiments. The development of skin organoids for different disease types is becoming a hot topic in translational research. Fifthly, in the field of medical beauty, in addition to laser and injection therapy, there is also great potential for the research and development of innovative cosmetic raw materials, such as peptides and nucleic acid materials, which have multiple effects and are one of the important directions for transformation. In addition, the improvement of medical beauty laser instruments and household phototherapy instruments in clinical practice also belongs to the category of transformation.

Regarding whether AI technology can shorten the conversion cycle, in practice, applications such as AI assisted diagnosis, as an important component of medical model innovation, are already optimizing the diagnosis and treatment process, improving efficiency, and helping to accelerate the implementation process from technology to application. Therefore, it can be considered that AI technology has a positive effect on shortening the conversion cycle. Overall, the transformation of scientific research into clinical practice is a multi-path and multi-level systematic engineering that requires the coordinated promotion of basic research, clinical needs, industrial capital, and policy support.

You have hosted and participated in multiple skin disease prevention and treatment exchanges with top institutions in Europe and America. What are the advantages of China's research and practice in this field from an international perspective? What is the most urgent issue in the prevention and treatment of skin diseases in China at present? What are the complementary and mutually beneficial aspects of clinical practice, scientific research, or education between China and foreign countries?

Chen Hongxiang: I worked for one year at Kyushu University in Japan, and then worked for three years at the Skin Biology Research Center of Massachusetts General Hospital at Harvard Medical School in the United States. The center has multiple collaborations with Shiseido Corporation in Japan. Afterwards, my supervisor in the United States was an authority in the field of melanocyte and melanoma research, and my supervisor in Japan was also the chairman of the first East Asian Dermatology Conference. These experiences have deeply impressed me with the importance of international exchanges in the prevention and treatment of skin diseases. After returning to China, especially since joining Zhongnan Hospital of Wuhan University, a large number of international exchange activities have been continuously carried out. We have invited many top international experts to China, including Professor John Y.M. Koo, a top five dermatologist in North America, Professor Harry L. Winfield, Director of the Cleveland Center for Dermatology, and Professor Luis Puig, Chair of the European EADV Psoriasis Working Group. By inviting them for in-depth communication and relevant training, we have gained a lot.

Through these exchanges, we have not only seen China's advantages, but also recognized our own shortcomings. We once invited an American expert to visit the laboratory of Wuhan University School of Medicine, and he highly praised our research platform, believing that its ability to combine clinical and scientific research is not inferior to any platform in the world. Specifically, China's advantages are mainly reflected in: firstly, extremely abundant clinical resources, large patient base, and wide disease spectrum; Secondly, dermatologists have accumulated rich clinical experience in outpatient clinics for a long time; Thirdly, the efficiency of medical services is high. Patients can seek medical treatment by registering on the same day, with short waiting times and low costs for surgery. During my six years working in Shenzhen, Hong Kong residents often underwent gastroscopy, dental visits, or various surgeries. In contrast, in the United States, it often takes four to six hours to see a doctor when seeking emergency treatment, and the convenience of medical care in China is obvious. In addition, the resources of integrated Chinese and Western medicine with Chinese characteristics are very rich, and the digital prospect is broad. Internet medicine, mobile payment, online consultation, etc. are developing rapidly, which are rare in foreign countries.

Of course, we also need to be aware that Europe and America have formed a very standardized and perfect system through long-term development, with rich experience in new drug research and development, clinical research, guideline formulation, queue construction, and medical education, which is very worthy of our serious study. Through complementary advantages, we can promote mutual development between both parties. China can improve its research quality by leveraging the standardized systems of Europe and America, and Europe and America can also collaborate by utilizing China's abundant clinical resources and efficient digital healthcare platforms. This is an important direction for complementary learning between China and foreign countries in clinical, scientific research, and education.

China has been providing medical assistance to Southeast Asia for many years. Focusing on the field of skin disease prevention and treatment, what mature clinical experience or advantages do you think China has that Southeast Asian countries can learn from?

Chen Hongxiang: Actually, the onset of skin diseases is also related to latitude, time, and other factors. From the perspective of biological evolution, there is not much difference in ethnicity between China and Southeast Asia. In terms of climate, Southeast Asia is mainly characterized by humid and hot environments, with abundant sun exposure, which is very similar to southern China. Therefore, the spectrum of skin diseases is also relatively close.

Based on this background, China has several mature experiences in the field of skin disease prevention and treatment that Southeast Asian countries can learn from. Firstly, the standardized diagnosis and treatment pathway for common skin diseases has become very mature. For diseases with high incidence rate, such as fungal infection, eczema, urticaria, acne, psoriasis, herpes zoster, and bacterial infection, Chinese grass-roots doctors have accumulated rich experience in diagnosis and treatment through a large number of clinical practices. Secondly, leveraging the experience of large-scale tertiary hospitals to drive the construction of grassroots medical consortia. For example, in Shenzhen, one hospital can manage more than 80 community health centers; In Hubei, as the main unit of the provincial physician association, it covers dozens or even hundreds of institutions through training, consultation, referral, remote guidance, and other methods. This systematic experience, which is linked by specialized disease construction and medical consortia, is very helpful for optimizing the allocation of regional medical resources. Thirdly, telemedicine and AI assisted follow-up have good applicability in the field of dermatology. Through images and medical records, common diseases can be classified and difficult cases can be referred and consulted, improving service efficiency. Fourthly, the combination of traditional Chinese and Western medicine for the treatment of skin diseases has a good acceptance in Southeast Asia. Due to the high usage rate of traditional Chinese medicine and natural medicines among local residents, the integrated model of Chinese and Western medicine is easy to implement and promote.

In addition, many skin diseases are closely related to lifestyle, hygiene habits, sun exposure, and other factors. China's health education and public health experience in these areas can also be shared. Overall, China and Southeast Asia have a high degree of similarity and complementarity in the prevention and treatment of skin diseases. Both sides can engage in two-way exchanges and cooperation in disease spectrum research, medical advantages, public health construction, and other aspects to jointly improve the level of regional skin disease prevention and treatment.

Since serving as the director of the Dermatology Department at Zhongnan Hospital, you have carried out multiple tasks in the construction of medical consortia, the development of sub specialties, and international exchanges. What core ideas have you developed in terms of discipline construction and team management?

Chen Hongxiang: Firstly, public hospitals serve as a foundation for the health of the people, aiming to solve as many problems as possible. At the same time, there are over 3000 diseases in dermatology, and it is impossible to cover them all. Not all skin diseases are common, but common and frequently occurring diseases must be classified and covered. Therefore, it is very important to have clear direction and specialized disease construction. Our department focuses on difficult to treat diseases such as psoriasis, atopic dermatitis, urticaria, hair loss, vitiligo, skin tumors, infectious skin diseases, and lupus erythematosus. We have established specialized disease clinics and standardized procedures with a particular emphasis.

Just like Jin Yong's novels strung together into a poem: "Flying snow shoots at white deer in the sky, laughing book hero leans on green mandarin." Our dermatology department also has its own "poem": "Relieve pain, relieve itching, eliminate stubborn ringworm, nourish skin, moisturize hair, and rejuvenate appearance. Pain relief "mainly targets postherpetic neuralgia, and about one-third to one fourth of patients in the ward have herpes zoster, requiring a balance between antiviral therapy and pain relief; 'Antipruritic' refers to the most prominent itching symptoms of allergic diseases such as eczema, drug rash, urticaria, contact dermatitis, etc; 'Removing stubborn ringworm' refers to stubborn skin diseases such as psoriasis and lupus erythematosus; 'Zifu' emphasizes the repair of the skin barrier and the application of innovative cosmetic ingredients; Runfa focuses on hair medicine, covering drugs and hair transplantation, with a high market demand; 'Rejuvenation' refers to medical beauty, including laser, injection, and skin surgery. The selection of the main development direction not only covers a wide range of diseases, but also achieves moderate focus.

In terms of team management, I insist on building a good team culture internally, which is not just about simple division of labor, but also about making everyone clear in direction, finding the right position, and forming a joint force, with the participation of medical, nursing, and technical positions. Externally, it is not only necessary to develop within the province and domestically, but also to attach importance to international exchanges, learn advanced international concepts, and introduce China's experience. I strongly encourage young people to read more international literature, attend international conferences, and actively go global. Although dermatology may seem like a small department, it relies on a broad background of university disciplines, platforms, and overall health.

Based on the current situation, what are your future focus areas in the field of dermatology?

Chen Hongxiang: My future focus in the field of dermatology will mainly be on two aspects. One is immune skin disease. Such diseases as psoriasis, atopic dermatitis, urticaria, vitiligo, etc., have a high incidence rate, often involving multiple organs and affecting the whole life cycle, so they are taken as the key direction of clinical research. The second is medical beauty. Medical beauty encompasses laser, injection, dermatology, and other fields, and also intersects with plastic surgery. Any sub specialty or single disease can be done well, and the demand of the general public is very high, such as comprehensive treatment of hair diseases, scars, vascular tumors, underarm odor, etc., all of which have broad development space. At the same time, the field of medical beauty also aligns with the two transformation directions we mentioned: one is the intersection of medicine and engineering, focusing on the research and development transformation of phototherapy and medical beauty laser equipment; The second is the transformation of innovative raw materials for cosmetics, especially the development of functional cosmetics. Whether it's clinical practice or research translation, these two directions will be my future work focus.

Previous
Eagle Eye Whistle, Digital Breakthrough: Strategic Upgrade of Blue Shield Security - Exclusive Interview with Liu Yueming, the Leader of Huangshi Blue Shield

Next
返回列表

HOME

Qingqiao View

Confined Space

Low-altitude Patrol

Digital Defence

G5687

Biomedicine

About Qingqiao

contact us

Service number

G5687